Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Lactoferricin B (LfcinB) peptide icon, one bubble per amino acidLactoferricin B (LfcinB)25 residues (approx.)FKCRRWQWRMKKLGAPSITCVRRAFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Lactoferricin B (LfcinB)

ImmuneResearch
~2-4 hours half-life (estimated)·Injection/Topical·8w on / 4w off

Also known as: LfcinB, Lfcin B, bovine lactoferricin

Two hundred and ninety-seven PubMed papers cover this 25-amino-acid fragment, and not one of them tested it in a human being. Lactoferricin B (LfcinB) is the antimicrobial core of bovine lactoferrin, released naturally when your stomach digests milk protein. In cell culture, it kills bacteria, fungi, and parasites by punching holes in their membranes. It also shows selective cytotoxicity against cancer cell lines while leaving healthy cells alone. The catch: zero human clinical trials exist at any phase. No injectable form has ever been given to a person under controlled conditions. Researchers studying antimicrobial resistance and innate immunity keep circling back to LfcinB because the preclinical data genuinely stands out.

What Is Lactoferricin B (LfcinB)?

Two hundred and ninety-seven published studies, and not a single human has been injected with this peptide under clinical observation. That gap defines Lactoferricin B (LfcinB, residues 17-41 of bovine lactoferrin, CAS 146897-68-9).

Bellamy and colleagues first isolated it in 1992 [1]. They found that pepsin digestion of cow milk lactoferrin releases a 25-residue fragment (FKCRRWQWRMKKLGAPSITCVRRAF) with antimicrobial potency far exceeding the parent protein. The mechanism is straightforward: LfcinB carries a net charge of roughly +8 at physiological pH. That cationic charge lets it bind to negatively charged microbial membranes and disrupt them directly, a carpet-like or toroidal pore model that makes resistance development harder than with conventional antibiotics.

Beyond killing microbes, LfcinB shows two other properties that keep it in the research spotlight. Eliassen and colleagues [2] found it killed mouse fibrosarcoma, melanoma and colon cancer cells, and it shrank fibrosarcoma tumors in mice by breaking tumor cell membranes. Separately, the peptide stimulates macrophage activation through TLR4 signaling and boosts NK cell cytotoxicity through granzyme B and perforin upregulation.

The practical reality? No Phase I toxicology data. No pharmacokinetic study in any species for the subcutaneous route. The 50, 100, and 200 mcg dosing tiers listed on this page are extrapolated from in vitro concentrations, not from anything resembling a human dose-finding study. Community use is nonexistent; zero Reddit threads, zero forum protocols, zero anecdotal reports exist. LfcinB sits in a peculiar spot: a well-published research peptide that nobody outside a laboratory has touched.

How Lactoferricin B (LfcinB) Works

LfcinB's primary killing mechanism depends on electrostatics. The peptide's arginine and lysine residues (giving it that +8 net charge) are attracted to negatively charged components of microbial membranes. In Gram-negative bacteria, the target is lipopolysaccharide; in Gram-positive species, lipoteichoic acid.

Once bound, the amphipathic structure inserts into the lipid bilayer. This causes membrane depolarization, pore formation, and cytoplasmic leakage. The direct membrane attack makes classical resistance mechanisms less relevant, since bacteria would need to fundamentally restructure their outer surfaces.

Against cancer cells, a different vulnerability is targeted. Cancer cells expose phosphatidylserine, a negatively charged membrane lipid, on their surface. Short peptides derived from human lactoferricin kill melanoma cells by binding it (Riedl 2014, PMID 24838743 (opens in a new tab)); that work tested human-derived peptides, not LfcinB. In Eliassen's mouse study, LfcinB broke open tumor cell membranes until the cells lysed [2].

The immunomodulatory arm works through TLR4 on macrophages. LfcinB stimulates NF-kB signaling, which drives production of IL-6 and TNF-alpha and increases phagocytic capacity. NK cells respond with upregulated granzyme B and perforin expression, boosting their tumor-killing activity.

All three mechanisms are confirmed only in cell culture and animal models. Whether these pathways activate meaningfully at doses achievable through subcutaneous injection in a human is completely unknown.

Lactoferricin B (LfcinB) Benefits

  • Lactoferricin B benefits center on antimicrobial defense, immune activation, and selective anticancer activity, all documented in preclinical models.
  • Broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and parasites confirmed across dozens of in vitro studies (review covers the full range)[3].
  • Direct membrane disruption as the primary killing mechanism, which reduces the probability of classical resistance pathways compared to target-specific antibiotics. Bacteria can't easily mutate away a charge-based attack on their outer membrane.
  • Killed mouse fibrosarcoma, melanoma and colon cancer cells and shrank fibrosarcoma tumors in mice in the Eliassen et al. study [2]. That study had no normal-cell comparison.
  • Anti-biofilm activity against Pseudomonas aeruginosa, one of the most clinically stubborn biofilm-forming species. In lab tests, paired (dimeric) lactoferricin-derived peptides blocked biofilm formation at low concentrations and sometimes cleared existing biofilms (in vitro)[4].
  • Macrophage activation through TLR4/NF-kB signaling and NK cell stimulation via granzyme B/perforin upregulation, offering a two-pronged innate immune boost in animal models.
  • Every one of these benefits lacks human confirmation. The preclinical evidence base is large (297 PubMed papers), but the translational gap to human use is total.

Lactoferricin B (LfcinB): Science vs Community Consensus

Science Only
Scientific Evidence
None
Based on 6 key studies·Research only

Broad-spectrum antimicrobial and selective antitumor activity confirmed extensively in vitro and in animal xenograft models.

Dosing studied: No human dosing established. In vitro concentrations of 50–100 mcg/mL used in cell culture cannot be translated to injectable systemic doses without pharmacokinetic justification.
Read the evidence (key study, limitations)

No human clinical trial data exists at any phase. Translational gap between preclinical evidence and human use is total.

Key Study

Bellamy et al. 1992 (PMID 1490908): original isolation/characterization; Eliassen et al. 2002 (PMID 12529985): direct antitumor effect on mouse fibrosarcoma, melanoma and colon cancer cells

Limitations

Zero human trials at any phase. No Phase I toxicology study. No in vivo PK study for SC route in any species. All site dosing tiers (50/100/200 mcg) extrapolated from in vitro MIC concentrations without pharmacokinetic basis. Half-life (2–4h) is estimated from structural analogy to similar cationic AMPs, not measured.

Community Experience
Weak
3.5/5
Based on ~0 user reports (confirmed via Reddit search)

No community use base.

Community dosing: No community dosing data exists.
Read the reports

Zero Reddit threads, no anecdotal protocols, no user reports found across r/Peptides, Longecity, or any peptide forum.

What users report (0)
    Common issues (0)
      Science-Only Evidence

      Science has substantial preclinical data (~297 PubMed papers, 2024–2025 analog/conjugate work continuing). Community use is absent entirely. No bridge between active research interest and self-experimentation.

      Lactoferricin B (LfcinB) Dosage Guide

      SpeculativeResearch use only; no established human dosing protocol
      LevelDose / InjectionFrequency
      Beginner50 mcg
      DailyTrack
      Moderate100 mcg
      DailyTrack
      Aggressive200 mcg
      DailyTrack
      Note:

      LfcinB typically comes as lyophilized powder in 2 mg or 5 mg vials. It is not a mainstream research-peptide product; it is sold only as a lab reagent for research (~$85/mg for a 5 mg vial, up to $150-300+/mg).

      Reconstitution math for a 2 mg vial: add 2.0 mL bacteriostatic water. That gives you 1 mcg per mcL. A 50 mcg beginner dose equals 50 mcL, which is 5 units on a U-100 insulin syringe. For 100 mcg, draw 10 units. For 200 mcg, draw 20 units.

      Don't use saline or high-ionic-strength buffers for reconstitution. LfcinB aggregates and turns turbid at neutral pH in those solutions; stick with sterile water or low-concentration bacteriostatic water.

      Check the Certificate of Analysis for two things before using any vial: HPLC purity above 95% and mass spectrometry confirming the correct molecular weight of 3124 Da. The disulfide bond between Cys19 and Cys36 must be confirmed intact. Linear (reduced) LfcinB has substantially weaker antimicrobial activity.

      Cycling Protocol

      On Period
      8 weeks
      Off Period
      4 weeks

      Limited clinical cycling data. Based on antimicrobial peptide research protocols, 8 weeks on with a 4-week off period is a reasonable framework. Monitor immune markers and inflammatory cytokines during use.

      Calculate your Lactoferricin B (LfcinB) dose
      Free dosage calculator with syringe visualization

      Or use the universal Peptide Calculator for any peptide.

      Lactoferricin B (LfcinB) Protocols by Goal

      beginnerCommunity8 weeks (arbitrary: no clinical cycling data supports this)
      Speculative course (no human basis)
      Wk 1–8
      50 mcg · Daily · Subcutaneous

      Expected: Unknown: no human efficacy data at any dose

      Monitor: No validated monitoring protocol exists. Minimum: CBC at baseline and biweekly (hemolytic potential uncharacterized in humans), CMP at baseline, inflammatory markers (CRP, IL-6) at baseline and week 4.

      How to Use Lactoferricin B (LfcinB)

      1. 1
        Step 1

        Remove the lyophilized LfcinB vial from frozen storage and allow it to reach room temperature (5 to 10 minutes). Do not heat.

      2. 2
        Using a fresh syringe, draw 2.0 mL of bacteriostatic water

        Insert the needle through the rubber stopper and direct the stream gently down the inner wall of the vial. Do not inject directly onto the powder.

      3. 3
        Swirl gently until fully dissolved

        The solution should be clear and colorless. If turbid or containing particles, do not use; LfcinB may have aggregated due to buffer incompatibility.

      4. 4
        Step 4

        For a 50 mcg dose from the 2 mg/2 mL reconstitution (1 mcg/mcL): draw 5 units on a U-100 insulin syringe. For 100 mcg: draw 10 units. For 200 mcg: draw 20 units.

      5. 5
        Step 5

        Clean the injection site on the abdomen or upper arm with an alcohol swab. Use a 29 or 30-gauge insulin needle.

      6. 6
        Pinch the skin and insert the needle at a 45-degree angle

        Inject slowly over 30 to 60 seconds. Slow injection reduces local irritation from the cationic charge.

      7. 7
        Withdraw the needle and apply light pressure

        Do not rub the site.

      8. 8
        Step 8

        Return the reconstituted vial to the refrigerator (2-8 degrees C) immediately. Use within 14 days. Do not freeze reconstituted solution.

      Alternative Routes

      Topical

      Higher local concentrations (100–500 mcg/mL in hydrogel or saline) achievable without systemic PK or hemolytic concerns

      Topical route avoids the uncharacterized systemic hemolytic threshold risk. Strongest preclinical antimicrobial data is in topical/ex vivo wound and biofilm models. 2024 MDPI Molecules paper (LfcinB–ciprofloxacin conjugate) also used topical application in biofilm models.

      Oral

      Would require very large oral doses to achieve any systemic exposure; no dose established

      LfcinB is naturally generated from dietary bovine lactoferrin during peptic digestion (PMID 9920391). Supplemental oral LfcinB also likely degraded. Intact oral lactoferrin (GRAS status; studied at 100 mg–4.5 g/day) is the better-established oral option if immune or antimicrobial support is the goal.

      Mixing your own vial? Use the Lactoferricin B (LfcinB) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

      Lactoferricin B (LfcinB) Stacking Protocols

      Works With

      Avoid

      Immunosuppressants (cyclosporine, tacrolimus, corticosteroids)

      Pharmacological antagonism: LfcinB promotes immune activation via TLR4/NF-kB signaling and directly counteracts immunosuppressive mechanisms. Risk of precipitating rejection flares or autoimmune exacerbation in immunosuppressed patients.

      Do not combine
      Anionic excipients or high-concentration detergents (SDS, anionic surfactants)

      Charge neutralization: LfcinB's net charge of approximately +8 at physiological pH is essential for membrane-disrupting antimicrobial activity. Anionic compounds can inactivate the peptide or alter aggregation state unpredictably.

      Estimated Cost

      Lactoferricin B (LfcinB) Side Effects

      The most serious concern with Lactoferricin B is that nobody knows its human safety profile. Zero Phase I toxicology data exists. Zero humans have been injected with this peptide under any controlled protocol. Every safety statement below comes from in vitro assays and animal models.

      Hemolytic potential is the risk that deserves the most attention. Cationic antimicrobial peptides as a class can disrupt mammalian red blood cell membranes at high concentrations. In vitro, native LfcinB appears non-hemolytic up to approximately 100 mcg/mL, and a tetrameric form showed no hemolysis below roughly 500 mcg/mL. But the threshold for systemic hemolysis after subcutaneous injection in a living human? Completely uncharacterized. The jump from petri dish to bloodstream involves absorption kinetics, protein binding, and tissue distribution that change the math entirely.

      Injection site reactions are expected rather than surprising. LfcinB's strong positive charge interacts with subcutaneous tissue and can cause local redness, swelling, and irritation. Keeping injection volume small (50 mcL or less) and injecting slowly over 30 to 60 seconds may help reduce local reactivity, but this is extrapolated from general cationic peptide handling, not from LfcinB-specific data.

      Immunostimulatory overshoot is a theoretical concern. LfcinB activates NF-kB signaling and drives production of pro-inflammatory cytokines IL-6 and TNF-alpha. In someone with an underlying autoimmune condition, sustained immune activation could trigger or worsen flares. This is a known class effect of immunostimulatory peptides, not something specific to LfcinB, but the absence of human dose-response data makes the risk boundary invisible.

      Bovine protein cross-reactivity matters. LfcinB retains the sequence FKCRRWQWRMKKLGAPSITCVRRAF from bovine lactoferrin. Anyone with cow milk protein allergy has a genuine cross-reactivity risk. This is not hypothetical; it is a direct structural concern.

      Published side effect data from the scientific literature [3]: GI discomfort reported with oral administration in animal studies. No systemic toxicity observed at concentrations tested in cell culture and animal models.

      Community-reported side effects: none exist. Zero user reports across Reddit, Longecity, or any peptide forum.

      When to stop immediately: any injection site reaction beyond mild transient redness, fever, systemic symptoms, urticaria, angioedema, or any laboratory evidence of hemolysis (falling hemoglobin, rising indirect bilirubin, reticulocytosis). There is no established safety window to guide dose adjustment. If something looks wrong, stopping is the only defensible response.

      Pregnancy and breastfeeding: no human safety data available. LfcinB is contraindicated during pregnancy and lactation.

      Common Issues & Solutions

      Injection site erythema and mild swelling expected due to cationic charge interacting with subcutaneous tissue: small injection volume (≤50 µL) and slow administration (30–60 seconds) reduces local reactivity.

      If reconstituted solution appears turbid or forms precipitate: LfcinB is prone to aggregation at neutral pH in high-ionic-strength buffers. Use sterile water or low-concentration bacteriostatic water; do not mix directly into saline.

      Verify correct disulfide bond formation via COA mass spec before use: linear (reduced) LfcinB has substantially weaker antimicrobial activity than the native disulfide-bonded form.

      No dose escalation guidance exists from any human trial: do not assume in vitro MIC concentrations (50–100 mcg/mL) translate to safe or effective SC injection doses.

      Bovine milk protein allergy is a genuine contraindication: LfcinB retains the FKCRRWQWRMKKLGAPSITCVRRAF sequence from bovine lactoferrin; cross-reactivity risk is real.

      Ask AI about this page

      Ask AI for a second opinion on Lactoferricin B (LfcinB) dosing and side effects

      Contraindications

      • Known hypersensitivity to lactoferrin or bovine milk-derived proteins
      • Pregnancy and breastfeeding: no human safety data available
      • Active autoimmune conditions: immunostimulatory effects may exacerbate autoimmune flares
      • Severe hemolytic anemias: cationic peptides may have dose-dependent hemolytic potential
      • Concurrent immunosuppressive therapy: LfcinB may counteract immunosuppression
      • Individuals with cow milk protein allergy (potential cross-reactivity)
      • Active cancer undergoing immunotherapy (checkpoint inhibitors): additive immunostimulation via NF-kB/NK cell pathways could amplify immune-related adverse events

      Drug Interactions

      • Immunosuppressants (cyclosporine, tacrolimus, corticosteroids): LfcinB promotes immune activation, potentially counteracting immunosuppressive effects
      • Conventional antibiotics (greater combined effects reported with ampicillin, gentamicin): may allow dose reduction of antibiotics
      • Anticoagulants: lactoferrin-derived peptides may have mild anti-thrombotic properties; monitor clotting parameters
      • Iron supplements: lactoferricin retains partial iron-binding capacity from parent lactoferrin
      • Other cationic antimicrobial peptides: additive or greater membrane-disrupting effects

      Product Quality

      Recommended Monitoring

      TestWhenTarget
      Complete Blood Count (CBC) with differentialBaseline, then every 2 weeks during useHemoglobin stable; no increase in indirect bilirubin, reticulocytes, or decrease in RBC count
      Comprehensive Metabolic Panel (CMP)Baseline and at week 4Not listed
      Inflammatory markers (CRP, IL-6)Baseline, week 2, week 4Not listed
      Injection site assessmentEach injectionNot listed
      Complete Blood Count (CBC) with differential

      Detect hemolytic changes: cationic AMPs have dose-dependent hemolytic potential. LfcinB hemolytic threshold in humans completely uncharacterized (non-hemolytic ≤100 mcg/mL in vitro; tetrameric form threshold ~500 mcg/mL).

      Comprehensive Metabolic Panel (CMP)

      Baseline liver and kidney function given complete absence of human toxicology data

      Inflammatory markers (CRP, IL-6)

      Verify expected immunostimulatory response is within normal range; detect excessive inflammatory activation indicating adverse immune reaction

      Injection site assessment

      Monitor for progressive sensitization, worsening erythema, induration, or systemic hypersensitivity signs (urticaria, angioedema)

      Lactoferricin B (LfcinB) Before and After

      Minutes to Hours

      Rapid membrane interaction with target microorganisms. In vitro bactericidal activity observed within 15-60 minutes at effective concentrations.

      Days 1-3

      With repeated dosing, sustained antimicrobial pressure on target pathogens. Early macrophage activation and increased phagocytic activity.

      Weeks 1-2

      Measurable enhancement of innate immune markers. Elevated NK cell activity in animal models. Anti-biofilm effects shown only in lab dishes so far.

      Weeks 3-4

      Peak immunomodulatory effects in research models. Reduction in bacterial colonization in chronic infection models.

      Weeks 5-8

      Continued antimicrobial and immunomodulatory support. Evaluate biomarkers for efficacy and safety. Consider transitioning to off-cycle.

      What to Expect

      Minutes to hours: After subcutaneous injection, LfcinB is estimated to reach peak absorption within 30 to 60 minutes, based on structural analogy to similar cationic antimicrobial peptides. The estimated half-life of 2 to 4 hours means rapid proteolytic clearance. No in vivo pharmacokinetic study exists for the SC route in any species. Injection site redness and mild swelling are possible from the peptide's cationic charge interacting with subcutaneous tissue. No user reports exist to confirm or deny these estimates.

      Days 1 to 3: With repeated dosing, rodent models show macrophage activation and increased phagocytic activity. Nitric oxide production rises and phagocytic capacity improves in these animal studies. No human data, no community reports.

      Weeks 1 to 2: Animal models demonstrate raised NK cell cytotoxicity and improved innate immune markers during this window. Anti-biofilm effects against P. aeruginosa have been shown only in lab dishes so far, not in infection models [4]. Still no human data, still no community reports.

      Weeks 3 to 8: Peak immunomodulatory effects and reduction in bacterial colonization appear in chronic infection animal models. Whether any of this translates to humans is completely unknown. The community has generated zero experience reports. Safety monitoring (CBC every 2 weeks, CMP at week 4, inflammatory markers at weeks 2 and 4) is the minimum responsible framework during this speculative window.

      Detailed Timeline: Science vs Community

      Minutes to hours
      Science

      SC absorption estimated at Tmax ~30–60 min based on structural analogy to similar cationic AMPs. Short estimated half-life (~2–4h) means rapid proteolytic clearance. No in vivo PK study in any species for SC route.

      Community

      No user reports exist.

      Days 1–3
      Science

      Macrophage activation and increased phagocytic activity demonstrated in rodent models at repeated doses. Elevated nitric oxide production and enhanced phagocytic capacity.

      Community

      No user reports exist.

      Weeks 1–2
      Science

      Elevated NK cell cytotoxicity and enhanced innate immune markers demonstrated in animal models. Anti-biofilm activity against P. aeruginosa has been shown in lab dishes only (PMID 32871093).

      Community

      No user reports exist.

      Weeks 3–8
      Science

      Peak immunomodulatory effects and reduction in bacterial colonization in chronic infection animal models. Efficacy translation to humans completely unknown.

      Community

      No user reports exist.

      Pharmacokinetics

      Half-Life
      3h
      Bioavailability
      SC: estimated 40-60%; oral: <5% due to gastrointestinal proteolysis
      Tmax
      ~30-60 minutes (SC)
      Data Confidence
      low

      Source: Estimated half-life of 2-4 hours based on in vivo studies of cationic antimicrobial peptides of similar size and charge (PMID 16261252)

      Pharmacokinetics: Active Dose Over Time

      t½ = ~2-4 hours (estimated; rapid proteolytic degradation in vivo)

      Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

      Molecular Profile

      Amino Acids
      25
      Sequence
      FKCRRWQWRMKKLGAPSITCVRRAF
      HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
      Identifiers

      Who Should Consider Lactoferricin B (LfcinB)

      • Researchers studying antimicrobial peptide mechanisms and resistance
      • Scientists investigating anti-biofilm strategies against drug-resistant pathogens
      • Oncology researchers exploring selective anticancer peptides
      • Immunologists studying innate immune activation and NK cell biology
      • Researchers developing topical antimicrobial formulations
      • Food scientists investigating natural preservative peptides

      Related Peptides

      What Changed for Lactoferricin B (LfcinB)

      No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

      Peptide Schedule Research TeamReviewed Apr 8, 20266 Citations

      References

      1. [1]Lactoferricin B, a novel antimicrobial peptide derived from bovine lactoferrin (Biochem Biophys Res Commun 1992) (opens in a new tab)PubMed (opens in a new tab)PubMed
      2. [2]Evidence for a direct antitumor mechanism of action of bovine lactoferricin (Anticancer Res 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
      3. [3]Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties (Cell Mol Life Sci 2005) (opens in a new tab)PubMed (opens in a new tab)Review
      4. [4]Antibiofilm activity of lactoferrin-derived synthetic peptides against Pseudomonas aeruginosa PAO1 (Biochem Cell Biol 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed

      Related Tools

      Storage & Stability

      Before Reconstitution
      Store at -20°C for long-term stability, up to 2 years. Protect from moisture and light.
      After Reconstitution
      Refrigerate at 2-8°C, use within 14 days. Avoid repeated freeze-thaw cycles: aliquot upon reconstitution.
      Temperature
      -20°C (long-term) or 2-8°C (short-term)

      Frequently Asked Questions

      No injectable form has been tested in any human trial. The parent protein lactoferrin has GRAS status and has been studied orally at 100 mg to 4.5 g/day, but the isolated pepsin-cleaved fragment LfcinB has zero human clinical data. Everything known comes from cell culture and animal models.

      Here's the honest answer: they appear to be extrapolated from in vitro cell culture concentrations (50-100 mcg/mL), not from any human PK or clinical study. What works in a petri dish has no direct pharmacokinetic relationship to what achieves therapeutic levels via SC injection in a person.

      No human safety data exists for injectable LfcinB. In vitro, native LfcinB is non-hemolytic up to ~100 mcg/mL. But there's no established safety window, no Phase I toxicology study, and no dose-response data in any animal species for the SC route. Systemic hemolytic threshold is uncharacterized.

      LfcinB is the active antimicrobial fragment of bovine lactoferrin (residues 17-41). It has significantly broader and more potent antimicrobial activity than intact lactoferrin because the disulfide-stabilized beta-sheet structure exposes the cationic charge more effectively for membrane interaction.

      Oral bioavailability is estimated under 5% due to GI proteolysis. Interestingly, your stomach naturally generates lactoferricin from dietary lactoferrin during digestion, but whether supplemental oral LfcinB survives in meaningful amounts to reach systemic circulation is unestablished.